Last reviewed · How we verify
NCT04413747: YOCO
Yoga Pranayama Adjuvant to Treat Burden COVID-19
NA trial testing morning Yoga-based breathing support in Coronavirus Infection in 1,000 participants. Status unknown.
1 June 2021
Quick facts
| Lead sponsor | Health Ricerca e Sviluppo S.R.L. |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 1,000 |
| Start date | 15 August 2020 |
| Primary completion | 1 June 2021 |
| Estimated completion | 30 September 2021 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- morning Yoga-based breathing support
- pre_lunch Yoga-based breathing support
- pre_dinner Yoga-based breathing support
Conditions studied
- Coronavirus Infection — all drugs for Coronavirus Infection →
- Cytokine Storm — all drugs for Cytokine Storm →
- Mental Disorder — all drugs for Mental Disorder →
Sponsor
Health Ricerca e Sviluppo S.R.L.
Who can join
Adults 18 to 75, any sex, with Coronavirus Infection or Cytokine Storm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
COronaVIrus Disease or Severe Acute Respiratory Syndrome -CoV-2 or COVID-19, mortality occurs mainly from immunological behavior or by suicide after healing . In both cases, the causal link is coronavirus within the host response. The rationale of use of deep yoga breathing as adjuvant treatment to COVID-19 disease , is linked to the mechanical action to stimulate the vagus nerve through scalene and sternocleidomastoid muscles function of which the continuity of action bring to modulate upto suppress, the inflammatory reflex and pro-inflammatory cytokines overproduction and contextual lowering of the sympathetic stress response as a first cause of sleep and late mental disorders which can increase the annual suicide rate. An easily breathing medical Yoga protocol has been developed to test a cost-effective care provision, training, contact tracing and mass efficacy testing.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04413747
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronavirus Infection
Currently open trials in the same condition.
- NCT04885504 — Post COVID-19 Biorepository · recruiting
- NCT04445454 — Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection · Phase 1, PHASE2 · recruiting
- NCT04510025 — Capturing MultiORgan Effects of COVID-19 · recruiting
- NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04413747 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Health Ricerca e Sviluppo S.R.L.
- Last refreshed: 7 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04413747.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing